S&P Global Analysts Give Novartis AG (VTX:NOVN) a CHF 82 Price Target

Novartis AG (VTX:NOVN) received a CHF 82 price target from stock analysts at S&P Global in a report issued on Tuesday, July 18th. The brokerage presently has a “neutral” rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. Jefferies Group LLC set a CHF 103 price objective on shares of Novartis AG and gave the stock a “buy” rating in a research report on Friday, June 23rd. Barclays PLC set a CHF 65 price objective on shares of Novartis AG and gave the stock a “sell” rating in a research report on Friday, June 2nd. Deutsche Bank AG set a CHF 78 price objective on shares of Novartis AG and gave the stock a “neutral” rating in a research report on Wednesday, June 21st. Morgan Stanley set a CHF 75 price objective on shares of Novartis AG and gave the stock a “sell” rating in a research report on Monday, May 29th. Finally, Credit Suisse Group set a CHF 77 price objective on shares of Novartis AG and gave the stock a “sell” rating in a research report on Wednesday, July 5th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of CHF 84.60.

Novartis AG (NOVN) opened at 82.10 on Tuesday. The company’s 50-day moving average price is CHK 80.94 and its 200-day moving average price is CHK 77.24. Novartis AG has a 12-month low of CHK 67.40 and a 12-month high of CHK 84.35.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.